Retrospective study of 25 mg low dose rectal diclofenac for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.

Retrospective study of 25 mg low dose rectal diclofenac for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. - Efficacy and safety of 25 mg low dose rectal diclofenac for preventing PEP.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026434

Enrollment

200

Registered

2017-03-08

Start date

2016-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common bile duct stone, malignancy lesion, benign lesion

Interventions

The patients in diclofenac group were recived 25 mg rectal diclofenac 20 minutes before ERCP The patients in control group were not received rectal diclofenac before ERCP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The ERCP cases for common bile duct stone, malignancy lesions, or benign lesion

Exclusion criteria

Exclusion criteria: Concomitant acute pancreatitis, peptic ulcer, rectal disease, aspirin-induced asthma, and sever kidney dysfunction.

Design outcomes

Primary

Measure	Time frame
The frequency of PEP.	—

Secondary

Measure	Time frame
The frequency of occurrence of post-ERCP hyperamylasemia and complication.	—

Countries

Japan

Contacts

Public ContactMitsuru Okuno

Japanese Red Cross Takayama Hospital Department of Gastroenterology

mkobdkl@yahoo.co.jp+81-577-32-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026